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EUS could detect ascites missed
by CT scan
I read with great interest the article by Lee
and colleagues (Gut 2005;54:1541–5) regard-
ing the accuracy of endoscopic ultrasonogra-
phy (EUS) in diagnosing ascites and
predicting peritoneal metastases in patients
with gastric cancer. I would like to thank the
authors for quoting our study.1 Lee and
colleagues commented that the sensitivity of
detection of ascites was lower in our study
and that this might be due to the use of
catheter probe. I would however like to point
out that such a comparison was unfair as the
two studies were fundamentally different in
two ways.
(1) The patient populations of the two
studies were different. Our study excluded all
patients with evidence of ascites on physical
examination or computed tomography (CT)
scan. We believe that there is no need for an
additional EUS to confirm the presence of
ascites in such patients. Moreover, such
patients should have paracentesis for cytol-
ogical examination rather than a locoregional
staging investigation like EUS.
During the study period of our paper
(September 1995 to January 2002), 89
patients had evidence of ascites on CT scan
or physical examination. There would be no
difficulty in detecting ascites in these patients
by EUS. If we included these patients, the
detection rate by EUS would have been 25.5%
(36+89/402+89 = 125/491). The overall inci-
dence of ascites was 29.5% (56+89/
402+89 = 145/491). The ‘‘adjusted’’ sensitiv-
ity would be 84.8% (34+89/56+89 = 123/145),
not much lower than the 87.1% reported by
Lee et al.
(2) CT scan was performed for all patients
in our study. Of the 89 patients who were
excluded from the study, 69 had evidence of
ascites on CT scan. The sensitivity of CT scan
for detection of ascites was 47.6% (69/145),
higher than the 16.1% sensitivity (combined
US and CT scan) reported by Lee et al. We
suspect the lower sensitivity may be due to
the predominant use of US scan (231
patients) rather than CT scan (99 patients)
in their study. A direct comparison however
is not possible as the study populations of the
two studies may be different.
In summary, I would like to applaud Lee et
al for their systematic study. The comment
that the sensitivity of detection of ascites was
lower in our study was unfair.
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Author’s reply
We would like to thank Dr Chu for his
interest in our paper and for supplementing
some of the data missing in his previous
publication.1 We agree that both studies had
fundamental difference in study design and
we would like to point out the major
difference for discussion.
One of the major differences lies in the
definition of presence of ascites. Chu et al
used positive laparoscopic detection of ascites
as the gold standard when comparing with
their endoscopic ultrasonography (EUS)
findings. However, in our study, we com-
bined all investigation results (ultrasound
(US), computed tomography (CT), EUS, and
operation) to determine the status of ascites.
We believe that a small amount of fluid, such
as several millilitres as detected by EUS,
might not be visibly appreciated during
operation.
Another major difference is the type of EUS
used in the two studies. We used an
echoendoscope (7.5–12 MHz) with a higher
penetration depth, which allowed scanning
through thick tumours. In contrast, Chu et al
used a miniprobe (20 MHz) in their study,
which actually had a limited depth of
penetration. This may explain why the overall
incidence of ascites was higher in our study
(37.2%) compared with Chu’s series (29.5%,
the supplemented data combining CT, physi-
cal examination, and operative finding). In
our study, EUS was more sensitive (87.1%)
than the operative findings (40.9%) in
detecting ascites. Therefore, we do not agree
with Chu’s conclusion that ‘‘laparoscopy and
laparotomy remain the reference standard for
the detection of ascites’’ as ‘‘ascites was
missed by EUS in nearly 40% of patients’’.1
We suspect if an echoendoscope was used in
Chu’s study, the sensitivity of EUS would
have increased and CT decreased, and the
projected results would then have come close
to ours.
In fact, CT scan is not our routine in the
preoperative assessment of patients with
gastric cancer, especially in those early gastric
cancers, or if EUS showed no local invasion.
There is no evidence in the literature showing
that CT scan is better than US in the
detection of ascites. CT scan could not be
used as the gold standard as, according to
Chu’s data, CT scan missed 20 patients with
ascites which was indeed detectable on
physical examination.
We are however agreed on the same
conclusion that ‘‘EUS is useful for the
detection of ascites in patients with gastric
carcinoma’’ and ‘‘The presence of ascites was
significantly associated with peritoneal seed-
ing’’.1
Y T Lee, E K W Ng
Institute of Digestive Disease, Chinese University of
Hong Kong, Hong Kong
Correspondence to: Dr Y T Lee, Institute of Digestive
Disease, Chinese University of Hong Kong, Shatin NT,
Hong Kong; leeytong@cuhk.edu.hk
Conflict of interest: None declared.
Reference
1 Chu KM, Kwok KF, Law S, et al. A prospective
evaluation of catheter probe EUS for the detection
of ascites in patients with gastric carcinoma.
Gastrointest Endosc 2004;59:471–4.
Anti-TNF-a therapy for orofacial
granulomatosis: proceed with
caution
A 36 year old female patient was reviewed at
the gastrointestinal clinic. She had, since the
age of 15 years, been affected by troublesome
orofacial granulomatosis (OFG) manifest as
lower lip swelling together with a midline
fissure. In the past she had received numer-
ous therapies, including intralesional and
systemic corticosteroid (short term benefit
only), cinnamon and a benzoate free diet
(lack of compliance), azathioprine (intoler-
ance), and topical tacrolimus (ineffective).
In 2001, due to increasing distress about
her appearance compounded by her forth-
coming wedding, we decided to treat her with
an infliximab infusion at 5 mg/kg. Within
seven days there was a noticeable improve-
ment, followed by complete healing of her
labial fissure six weeks later, just prior to her
wedding. Two weeks after this she found out
she was pregnant. She subsequently gave
birth to a healthy baby boy but failed to
attend the clinic and was lost to follow up for
four years.
On re-referral to the clinic in 2005, she was
in the midst of a course of oral prednisolone
(prescribed by her general practitioner) as her
OFG had once again become problematic. In
view of her excellent previous response to
anti-tumour necrosis factor a (TNF-a) ther-
apy coupled with the significant risks of an
infusion reaction if rechallenged with inflix-
imab (long drug ‘‘holiday’’ with no concomi-
tant immunosuppression), we elected to treat
her with subcutaneous adalimumab, 80 mg
initially and then 40 mg fortnightly. After
five weeks of treatment there was both a
subjective and objective improvement, with
partial healing of the midline fissure (figs 1,
2). At eight weeks the patient noted some left
sided facial pain and swelling just below the
corner of her mouth. She attended her dentist
who excluded any peridontal sepsis. Three
days later she was admitted to our unit with
fever sweats and worsening facial pain and
swelling (fig 3). Clinically she had a perioral
cellulitis with bilateral perioral swelling
and erythema, together with pyrexia and
raised inflammatory indices. She received
Figure 1 Pre-adalimumab treatment; swollen
lower lip with deep midline fissure.
Figure 2 At five weeks, after three
adalimumab injections; marked improvement in
midline fissure.
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intravenous benzylpenicillin and flucloxacil-
lin to which there was minimal response but
there was a rapid resolution of the cellulitis
with intravenous piperacillin. Her blood
cultures were negative. Adalimumab therapy
was terminated immediately.
OFG is a chronic inflammatory disorder of
the orofacial tissues characterised by non-
caseating granulomas on biopsy. 1 Numerous
Crohn’s therapies have been used to treat this
condition, although due to the relative rarity
of OFG, none has been subjected to random-
ised controlled trials. Thus physicians have to
base their treatment decisions on small case
series. Anti-TNF-a therapy has been used to
treat OFG, with success reported with both
thalidomide and infliximab.2 3 Adalimumab
is a recently developed fully human IgG1
monoclonal antibody to TNF-a and prelimin-
ary data have shown this drug to have similar
efficacy to infliximab in those Crohn’s
patients intolerant to4 or in whom response
has become attenuated5 with infliximab.
It has become commonplace for gastro-
enterologists to actively exclude sepsis when
considering infliximab therapy for inflamma-
tory bowel disease, as will be the case for
adalimumab if and when it is fully licensed.
This is clearly difficult in OFG, a disease
characterised by facial pain, swelling,
erythema, and mucosal breaks. In addition,
the oropharygeal mucosa, the presumed
portal of bacterial entry in this case, is
colonised by a wide variety of organisms in
health, thus swabbing this region prior to
anti-TNF therapy will almost certainly give
positive results, but is unlikely to assist in the
decision to give or withhold therapy.
Furthermore, patients will almost certainly
learn to self administer this medication and
without proper warnings it is conceivable
that patients could continue to take this
medicine in the context of worsening sepsis.
This case highlights that while anti-TNF-a
therapy may have a therapeutic role in OFG,
extreme caution and close monitoring must
be undertaken in those patients who receive
it.
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Adverse events in clinical trials
with azathioprine and
mesalamine for prevention of
postoperative recurrence of
Crohn’s disease
We read with great interest the study by
Ardizzone and colleagues (Gut 2006;55:47–
53) and the excellent review of Sands (Gut
2006;55:437–41) commenting on the efficacy
and side effects of azathioprine (AZA) in the
therapy of ulcerative colitis. Ardizzone et al
observed in their investigator blinded study,
which included patients with steroid depen-
dent ulcerative colitis, more mild to moderate
adverse events in azathioprine than in mesa-
lamine (5-ASA) treated patients (26% v 6%;
p = 0.046). However, only two of 36 patients
on AZA were withdrawn from the study
because of adverse events. We would like to
comment on the side effects of AZA, which
we observed in a double blind, double
dummy, randomised, prospective, multicen-
tre study on the efficacy and safety of AZA
(2.0–2.5 mg/kg/day) and 5-ASA (4 g/day) for
prevention of postoperative endoscopic recur-
rence in Crohn’s disease.
Seventy nine patients (AZA, 42; 5-ASA, 37)
were randomised within two weeks after
surgery. TPMT genotyping was performed at
baseline in order to exclude subjects with
homozygous TPMT deficiency. However, the
study was stopped prematurely because an
interim analysis revealed that the hypothesis
of superiority of AZA versus 5-ASA could not
be tested with the planned sample size. In 37
patients (AZA, 18; 5-ASA, 19) who completed
the study according to the protocol (treat-
ment for one year), the primary study end
point (treatment failure: severe endoscopic
relapse, withdrawal due to clinical relapse or
to adverse drug reaction) was evaluated.
Treatment failure was found to be equally
high in each group (AZA, 9 of 18; 5-ASA, 9 of
19; p = 1.00, two sided Fisher’s exact test).
Six of 18 patients on AZA and two of 19
patients on 5-ASA therapy were withdrawn
because of adverse drug reactions (33% v
11%; p = 0.12, two sided Fisher’s exact test);
reasons were leucopenia/anaemia (AZA, 1;
5-ASA, 1), elevated liver enzymes, arthralgia/
myalgia, vomiting, abdominal pain, macro-
scopic fecal excretion of study medication
(AZA, 1 each), and pancreatitis (5-ASA, 1).
Clinical or severe endoscopic relapse was
observed in three of 18 patients on AZA
therapy and in seven of 19 patients on 5-ASA
therapy (17% v 37%; p = 0.27, two sided
Fisher’s exact test). Considering all 79
patients, adverse events were reported in
approximately 70% of patients in each group
(AZA, 29 of 42; 5-ASA, 26 of 37). Furthermore,
in three of 42 ‘‘non-completers’’ an intolerable
adverse event led to withdrawal (AZA, ileus; 5-
ASA, cholecystitis, ankylosing spondylitis).
Two further trials investigating the efficacy
and side effects of AZA to prevent postoperative
relapse of Crohn’s disease have been published
recently.1 2
In an open label study by Ardizzone and
colleagues,1 adverse events were observed
more frequently (39% v 25%) in patients
receiving AZA (2 mg/kg/day) than in those
receiving 5-ASA (3 g/day). Fifteen of 69
patients in the AZA group and six of 69
patients in the 5-ASA group were withdrawn
because of adverse events (22% v 9%;
p = 0.04); reasons for withdrawal were leu-
copenia/thrombocytopenia (AZA, 7; 5-ASA,
0), elevated liver enzymes (AZA, 4; 5-ASA, 1),
pancreatitis (AZA, 3; 5-ASA, 0), epigastric
intolerance (AZT, 1; 5-ASA, 2), and increased
serum creatinine (AZT, 0; 5-ASA, 3). In a
double blind placebo controlled trial by
Hanauer and colleagues,2 nine of 47 (19%)
patients receiving a relatively low dose of
6-mercaptopurine (6-MP 50 mg/day), six of
44 (14%) patients receiving 5-ASA (3 g/day),
and four of 40 (10%) patients on placebo
were withdrawn from the study because of
adverse events, respectively; reasons for with-
drawal were diarrhoea (6-MP, 2, 5-ASA, 2),
leucopenia (6-MP, 2; 5-ASA, 0), alopecia
(6-MP, 2; 5-ASA, 0), elevated liver enzymes
(6-MP, 0; 5-ASA, 1), flatus, gastrointestinal
bleeding, phlebitis (6-MP, 1 each), and
allergic reaction, bowel obstruction, and
arthralgia (5-ASA, 1 each).
In summary, we could not provide evi-
dence for the superiority of AZA over 5-ASA
in our prospective clinical trial. In contrast
with the trials described above, we observed a
higher rate of adverse drug reactions leading
to withdrawal from the study in the AZA
group. Placebo controlled trials are needed
urgently to address the question of best
postoperative immunosuppressive manage-
ment.3 However, our observations indicate
the difficulties that may arise in future trials
for reaching an adequate statistical power to
provide a valid answer to this question.
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Figure 3 At eight weeks, after four
adalimumab injections; although the midline
fissure continued to heal, there was now a florid
bilateral perioral cellulitis and the patient was
systemically unwell.
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